Literature DB >> 28025445

Hypertension is a characteristic complication of X-linked hypophosphatemia.

Yoshie Nakamura1, Masaki Takagi, Ryojun Takeda, Kentaro Miyai, Yukihiro Hasegawa.   

Abstract

X-linked hypophosphatemia (XLH) is a group of rare disorders caused by defective proximal tubular reabsorption of phosphate. Mutations in the PHEX gene are responsible for the majority of cases. There are very few reports of long-term complications of XLH other than skeletal and dental diseases. The aim of this study was to identify the phenotypic presentation of XLH during adulthood including complications other than skeletal and dental diseases. The clinical and biochemical phenotype of 22 adult patients with a PHEX gene mutation were examined retrospectively from their medical records. 6 patients had hypertension. The average age of hypertension onset was 29.0 years. Secondary hyperparathyroidism preceded the development of hypertension in 5 patients. 1 patient developed tertiary hyperparathyroidism. 15 patients had nephrocalcinosis. 2 patients had chronic renal dysfunction. Patients with hypertension had a significantly lower eGFR (p=0.010) compared to patients without hypertension. No significant difference was found in any other parameters. To examine the genotype-phenotype correlation, 10 adult males were chosen for analysis. No significant genotype-phenotype correlation analysis was revealed in any of the complications. However, there was a possibility that the age at nephrocalcinosis onset was younger in the non-missense mutation group than in the missense mutation group (p=0.063). This study corroborated the view that early-onset hypertension could be one of the characteristic complications seen in XLH patients. Considering the limited number of our patients, further study is necessary to address a potential cause of hypertension. XLH patients require careful lifelong treatment.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28025445     DOI: 10.1507/endocrj.EJ16-0199

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  15 in total

Review 1.  Congenital Conditions of Hypophosphatemia Expressed in Adults.

Authors:  Gemma Marcucci; Maria Luisa Brandi
Journal:  Calcif Tissue Int       Date:  2020-05-14       Impact factor: 4.333

Review 2.  FGF23 and Associated Disorders of Phosphate Wasting.

Authors:  Anisha Gohil; Erik A Imel
Journal:  Pediatr Endocrinol Rev       Date:  2019-09

3.  Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients.

Authors:  Sean DeLacey; Ziyue Liu; Andrea Broyles; Sarah A El-Azab; Cristian F Guandique; Benjamin C James; Erik A Imel
Journal:  Bone       Date:  2019-07-02       Impact factor: 4.398

Review 4.  Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia.

Authors:  Andrea Trombetti; Nasser Al-Daghri; Maria Luisa Brandi; Jorge B Cannata-Andía; Etienne Cavalier; Manju Chandran; Catherine Chaussain; Lucia Cipullo; Cyrus Cooper; Dieter Haffner; Pol Harvengt; Nicholas C Harvey; Muhammad Kassim Javaid; Famida Jiwa; John A Kanis; Andrea Laslop; Michaël R Laurent; Agnès Linglart; Andréa Marques; Gabriel T Mindler; Salvatore Minisola; María Concepción Prieto Yerro; Mario Miguel Rosa; Lothar Seefried; Mila Vlaskovska; María Belén Zanchetta; René Rizzoli
Journal:  Nat Rev Endocrinol       Date:  2022-04-28       Impact factor: 43.330

5.  X-linked hypophosphatemia, obesity and arterial hypertension: data from the XLH21 study.

Authors:  Louisa Bloudeau; Agnès Linglart; Sacha Flammier; Aurélie Portefaix; Aurélia Bertholet-Thomas; Sanaa Eddiry; Anna Barosi; Jean-Pierre Salles; Valérie Porquet-Bordes; Anya Rothenbuhler; Christelle Roger; Justine Bacchetta
Journal:  Pediatr Nephrol       Date:  2022-06-27       Impact factor: 3.714

Review 6.  Phosphate Is a Cardiovascular Toxin.

Authors:  Maren Leifheit-Nestler; Isabel Vogt; Dieter Haffner; Beatrice Richter
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

7.  Risk of cardiovascular involvement in pediatric patients with X-linked hypophosphatemia.

Authors:  Olaya Hernández-Frías; Helena Gil-Peña; José M Pérez-Roldán; Susana González-Sanchez; Gema Ariceta; Sara Chocrón; Reyner Loza; Francisco de la Cerda Ojeda; Leire Madariaga; Inés Vergara; Marta Fernández-Fernández; Susana Ferrando-Monleón; Montserrat Antón-Gamero; Ángeles Fernández-Maseda; M Isabel Luis-Yanes; Fernando Santos
Journal:  Pediatr Nephrol       Date:  2019-01-04       Impact factor: 3.714

Review 8.  Pharmacological management of X-linked hypophosphataemia.

Authors:  Erik A Imel; Kenneth E White
Journal:  Br J Clin Pharmacol       Date:  2018-10-29       Impact factor: 4.335

Review 9.  FGF23 and its role in X-linked hypophosphatemia-related morbidity.

Authors:  Signe Sparre Beck-Nielsen; Zulf Mughal; Dieter Haffner; Ola Nilsson; Elena Levtchenko; Gema Ariceta; Carmen de Lucas Collantes; Dirk Schnabel; Ravi Jandhyala; Outi Mäkitie
Journal:  Orphanet J Rare Dis       Date:  2019-02-26       Impact factor: 4.123

Review 10.  FGF23, Hypophosphatemia, and Emerging Treatments.

Authors:  Erik A Imel; Andrew Biggin; Aaron Schindeler; Craig F Munns
Journal:  JBMR Plus       Date:  2019-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.